Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics, Inc.

Anika Therapeutics is a global joint preservation company focused on early intervention orthopedic care, offering solutions for joint pain and arthritis.

msh id	COM:ANIKA
symbol	ANIK
name	Anika Therapeutics, Inc.
homepage url	https://www.anikatherapeutics.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	357
crunchbase url	-
linkedin url	-
founders	-

market cap	389.26M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.09
growth cost of revenue	0.01
growth depreciation and amortization	-0.02
growth ebitda	0.42
growth ebitda ratio	0.46
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	0.1
growth gross profit ratio	0.03

COM:ANIKA

Anika Therapeutics

Last Close

17.18

21/11 21:00

Market Cap

389.26M

Beta: -

Volume Today

57.75K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	192.11M
cost of revenue	192.11M
depreciation and amortization	14.23M
ebitda	-11.22M
ebitda ratio	-0.07
eps	-5.64
eps diluted	-5.64
operating expenses	128.54M
operating income	-25.45M
operating income ratio	-0.15

accounts receivables	-1.31M
capital expenditure	-5.43M
cash at beginning of period	86.33M
cash at end of period	72.87M
inventory	46.39M
working capital ttm	128.71M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-